Healthcare, Pharma & Life Sciences

Pfizer Terminates Phase II Maplirpacept Trial Amid Recruitment Struggles, Keeps Focus on Blood Cancer Pipeline

Image

SHERIDAN, WYOMING – July 01, 2025 – Pfizer has announced the termination of its Phase II trial evaluating the investigational CD47-targeting fusion protein maplirpacept in diffuse large B-cell lymphoma (DLBCL), citing persistent recruitment difficulties that prevented the study from meeting enrollment targets. The decision, which affects a program inherited through the company’s $2.26 billion acquisition of Trillium Therapeutics in 2021, underscores ongoing challenges in advancing CD47 inhibitors while highlighting Pfizer’s continued commitment to its hematologic oncology pipeline.

Recruitment Roadblocks Halt Mid-Stage Development

Pharma M&A Reignites in June, Signaling Renewed Momentum Despite Regulatory Headwinds

Image
Messe Düsseldorf spotlights EuroShop 2026 start-ups focused on operational retail gains and scalable store tech

SHERIDAN, WYOMING – July 01, 2025 – A late surge of acquisitions in June has reenergized pharmaceutical M&A activity, with six major deals announced that propelled first-half 2025 totals to 32 transactions across the industry. This burst of dealmaking, highlighted by BioNTech’s $1.25 billion acquisition of CureVac and Eli Lilly’s $1.3 billion buyout of Verve Therapeutics, has analysts optimistic that the sector’s cautious stance may finally be easing.

Resilient M&A Amid Regulatory Uncertainty

The first half of 2025 was marked by significant headwinds for dealmakers, including political and regulatory turbulence. The deal flow in the first half was overall “relatively steady but cautious,” PwC said in the firm’s mid-year outlook, published June 18. There were about 32 deals in the biopharma space recorded for the first half, according to data from S&P Capital IQ and analyzed by BioSpace.

Ultrarare Disease Treatments Edge Closer with Platform Technologies and Precision Gene Editing

Image
EuroShop 2026 Publishes Seven-Stage Program to Help Retail Leaders Navigate AI, Marketing, and Store Design Decisions

SHERIDAN, WYOMING – July 01, 2025 – A groundbreaking collaboration that delivered a custom-made CRISPR therapy to a nine-month-old patient with CPS1 deficiency has ignited optimism that ultrarare diseases could soon be addressed on a broader scale, thanks to advances in delivery systems, precision gene editing, and regulatory pathways.

KJ’s treatment—the first of its kind—was made possible through contributions from Acuitas Therapeutics, Aldevron, and Integrated DNA Technologies (IDT), which manufactured and shipped the key components free of charge. The success has prompted key industry figures to ask: can this model be repeated to address the thousands of ultrarare conditions affecting patients worldwide?

The Case for Platform Technologies

FDA Grants Surge of Regulatory Approvals Across RSV, Cancer, and Hepatitis C Therapeutics in June 2025

Image
EuroShop 2026 Marks 60 Years With “Global Retail Festival” Format and Expanded Innovation Agenda

SHERIDAN, WYOMING – July 01, 2025 – A wave of pivotal FDA decisions in June 2025 is reshaping key segments of the pharmaceutical landscape, with new approvals spanning respiratory syncytial virus (RSV) vaccines, advanced cancer treatments, and the first-ever antiviral for acute hepatitis C. These regulatory moves not only expand therapeutic options for patients but also set the stage for intensified competition in critical markets, underscoring strategic opportunities for companies across the biopharmaceutical sector.

Moderna and Merck Drive RSV Market Expansion

Innovations in Dental 3D Printing Materials Propel Clinical Excellence and Workflow Integration

Image
Innovations in Dental 3D Printing Materials Propel Clinical Excellence and Workflow Integration

SHERIDAN, WYOMING - June 27, 2025 - A new wave of breakthroughs in 3D printing materials for dental applications is redefining the capabilities of digital dentistry, enabling practices to deliver faster, more precise, and highly customized patient care while maintaining clinical safety and efficiency.

Dental 3D printing has evolved rapidly over the past decade, with materials innovation playing a central role in expanding what's possible-from same-day night guards to definitive crowns. The industry's shift toward specialized, biocompatible resins developed exclusively for dental workflows is setting new standards in prosthetics quality, workflow integration, and patient outcomes.

A Decade of Material Evolution Unlocks Clinical Versatility

Digital Dentures Redefine Prosthetic Dentistry with Streamlined Workflows and Enhanced Patient Outcomes

Image
Digital Dentures Redefine Prosthetic Dentistry with Streamlined Workflows and Enhanced Patient Outcomes

SHERIDAN, WYOMING - June 27, 2025 - Digital dentures are transforming prosthetic dentistry, delivering a precise, efficient, and patient-friendly alternative to traditional dentures. By leveraging advanced technologies like 3D scanning, CAD/CAM design, and 3D printing, companies like SprintRay are pioneering a workflow that enhances comfort, fit, and aesthetics for patients, while reducing errors and appointment times for dental professionals.

Embracing Cutting-Edge Technology for Superior Results

Elevating Digital Denture Production: SprintRay Apex Resins Gain Validation on Carbon M-Series Printers

Image
Elevating Digital Denture Production: SprintRay Apex Resins Gain Validation on Carbon M-Series Printers

SHERIDAN, WYOMING - June 27, 2025 - Dental laboratories worldwide are set to benefit from a powerful advancement as SprintRay's Apex Base and Apex Teeth resins have been officially validated for use on Carbon's M-Series 3D printers, unlocking new levels of precision, aesthetics, and operational efficiency in digital denture fabrication.

Strengthening a Strategic Collaboration

The validation marks the latest milestone in the ongoing collaboration between SprintRay and Carbon, building on the prior success of SprintRay's OnX Tough 2 resin. By deepening this partnership, both companies are reinforcing their shared commitment to transforming dental workflows through innovative technologies designed to improve productivity and clinical outcomes.

Dentsply Sirona and Project 32 Deliver Advanced Dental Care to Amazonian Communities Through Digital Innovation

Image
Dentsply Sirona and Project 32 Deliver Advanced Dental Care to Amazonian Communities Through Digital Innovation

SHERIDAN, WYOMING - June 27, 2025 - In a landmark effort to expand access to high-quality oral healthcare, Dentsply Sirona, the world's largest diversified manufacturer of professional dental products and technologies, has successfully completed a week-long dental expedition in partnership with Brazilian NGO Project 32. This initiative, part of Dentsply Sirona's sustainability program "BEYOND: Taking Action for a Brighter World," brought advanced, free dental care to remote Amazonian communities, combining on-site and digital expertise to reach some of Brazil's most underserved populations.

Connecting Dentists and Patients Through Digital Dentistry

Dentsply Sirona Announces DS World Las Vegas 2025 with Strategic Focus on Connected Dentistry and Clinical Education

Image
Dentsply Sirona Announces DS World Las Vegas 2025 with Strategic Focus on Connected Dentistry and Clinical Education

SHERIDAN, WYOMING - June 24, 2025 - Dentsply Sirona has officially opened registration for DS World Las Vegas 2025, its flagship clinical education event, returning to the MGM Grand from September 25-27. Designed to empower dental professionals through innovation and knowledge-sharing, the event will spotlight Dentsply Sirona's Connected Dentistry proposition, with a strategic focus on digital integration, workflow optimization, and patient care advancement.

Driving Practice Efficiency Through Connected Technologies

This year's DS World will immerse attendees in the rapidly evolving landscape of digital dentistry, with a strong emphasis on data-driven, integrated technologies. From AI-powered tools to cloud-based collaboration, participants will gain actionable insights into how Dentsply Sirona's solutions-such as the DS Core platform-are reshaping modern dental practices.

Attendees will explore:

Dentsply Sirona Accelerates Primeprint 3D Workflow with Speed Upgrade and Integrated Nitrogenerator

Image
Dentsply Sirona Accelerates Primeprint 3D Workflow with Speed Upgrade and Integrated Nitrogenerator

SHERIDAN, WYOMING - June 24, 2025 - Dentsply Sirona has announced a major upgrade to its Primeprint Solution, enhancing 3D printing speeds and introducing the fully autonomous Primeprint Nitrogenerator to streamline post-processing workflows for dental labs and practices. These innovations are designed to improve throughput, reduce manual tasks, and reinforce the company's commitment to Connected Dentistry.

Faster Splint Manufacturing Enhances Efficiency

The upgraded Primeprint delivers twice the speed for splint production, notably impacting applications involving Primeprint Splint, Primeprint Splint SF, Primeprint Splint ST, as well as Model and Tray applications. Nightguards, for example, can now be produced in approximately 14 minutes, significantly reducing turnaround times.